Golimumab Shows Promise for the Treatment of Rheumatoid Arthritis

There are currently three TNF agents on the market for RA; among these, infliximab is a chimeric monoclonal antibody against TNF-α administered as an infusion.  Golimumab is similar to infliximab, except that it has been engineered to be fully human and is given as a subcutaneous injection. 

Does Postmenopausal Hormone Replacement Affect Rheumatoid Arthritis Outcomes?

Estrogens are known to modify immunologic responses and the modulation of rheumatoid arthritis (RA) disease activity during pregnancy is well documented.  However, whether physiologic replacement of estrogen and other hormones after menopause adversely affects RA outcomes is controversial. 

Arthritis News

Support for this site is provided through unrestricted educational grants from
Amgen, Abbott Immunology, Bristol-Myers Squibb, Centocor , and Genentech